Feb 5, 2025 · Invivyd creates medicines that are more potent and resistant to virus evolution than the human immune system. We deploy a proprietary integrated technology platform unique in the industry to assess, monitor, develop, and adapt to create best in class antibodies.

Feb 3, 2025 · About Invivyd Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies.

Invivyd is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases.

With our INVYMAB™ platform approach, we aim to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats.

Feb 3, 2025 · Invivyd previously guided expectations to finish 2024 with $65 million or more in cash and cash equivalents and targeted near-term (by end of 1H 2025) profitability with existing cash and cash ...

Jan 27, 2025 · Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies.

Mar 22, 2024 · PEMGARDA is the first authorized mAb from Invivyd’s novel technology platform approach designed to address the challenge of rapid viral evolution; Product availability in the U.S. anticipated imminently; Estimated cash and cash equivalents of $200.6 million as of December 31, 2023

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United...

Feb 3, 2025 · Invivyd announced positive data from its ongoing Phase 1/2 clinical trial of VYD2311, Invivyd’s novel monoclonal antibody candidate designed to be a superior alternative to COVID-19 vaccination ...

Feb 3, 2025 · Invivyd's ongoing randomized, double-blind, Phase 1/2 clinical trial is evaluating the safety and clinical pharmacokinetic (PK) profile of VYD2311 in 40 subjects across multiple routes of administration and dose levels for a single dose, and includes VYD2311 dosed intravenously (IV), intramuscularly (IM), and subcutaneously (SC) in four cohorts ...